RKDA
Arcadia Biosciences, Inc. (RKDA) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative cash conversion cycle indicates working-capital efficiency versus peers, but it is a fragile benefit because it does not offset weak underlying profitability.
Current and quick ratios are above 2.9x, giving RKDA better near-term liquidity than many micro-cap peers and reducing immediate refinancing pressure.
Zero debt-to-equity suggests limited balance-sheet leverage versus indebted peers, which lowers fixed-charge burden but also reflects constrained capital structure flexibility.
Net debt to EBITDA is modest at 0.38x, so leverage is not the primary structural constraint relative to peers with heavier debt loads.
Weaknesses
Return on invested capital is deeply negative at -95.6%, showing RKDA destroys capital versus peers that at least preserve invested capital.
The absence of reported operating and gross margins signals an unproven earnings base, leaving RKDA structurally weaker than peers with repeatable margin profiles.
A negative cash conversion cycle can reflect supplier financing rather than durable operating strength, so it does not compensate for weak profitability versus peers.
Limited leverage metrics and high liquidity do not create competitive advantage when the core business fails to generate positive returns on capital.
Opportunities
If RKDA can convert its liquidity cushion into operating scale, it has more runway than peers with tighter working capital to fund commercialization.
Low leverage leaves room to finance restructuring or growth initiatives without immediate balance-sheet stress, unlike more indebted peers.
Improving capital efficiency would have outsized impact because the current ROIC deficit is so large relative to peers, creating a clear re-rating pathway.
A stronger cash cycle position could support supplier terms and inventory discipline if management sustains it while rebuilding margins.
Threats
Persistent negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest while RKDA continues to consume capital.
If liquidity weakens, RKDA lacks the earnings power to self-fund operations, making it more vulnerable than profitable peers.
The absence of margin disclosure heightens execution risk, because peers with transparent and stable margins can command better financing and customer confidence.
Any deterioration in working-capital efficiency would quickly expose the business, since its current balance-sheet cushion is the main buffer against peer pressure.
Overall Score
RKDA’s structural positioning versus peers is weak because liquidity and low leverage are outweighed by deeply negative capital returns and an unproven margin base.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Arcadia Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
